Athenex Inc
F:2MT
Athenex Inc
Non-Reccuring Items
Athenex Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Athenex Inc
F:2MT
|
Non-Reccuring Items
-$3.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
Athenex Inc
Glance View
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
See Also
What is Athenex Inc's Non-Reccuring Items?
Non-Reccuring Items
-3.2m
USD
Based on the financial report for Dec 31, 2022, Athenex Inc's Non-Reccuring Items amounts to -3.2m USD.
What is Athenex Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
92%
Over the last year, the Non-Reccuring Items growth was 92%.
